Kidney Week

Abstract: FR-PO233

Renal and Cardiovascular (CV) Outcomes of Canagliflozin (CANA) According to Race and Ethnicity: A CREDENCE Secondary Analysis

Session Information

• Diabetic Kidney Disease: Advancing Treatment
  November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Diabetic Kidney Disease

• 602 Diabetic Kidney Disease: Clinical

Authors

• Levin, Adeera, University of British Columbia, Vancouver, British Columbia, Canada

Adeera Levin,

• Mahaffey, Kenneth W., Stanford University School of Medicine, Stanford, California, United States

Kenneth W. Mahaffey,

• Baldassarre, James S., Janssen Research & Development, LLC, Raritan, New Jersey, United States

James S. Baldassarre,

• Chu, Pei-Ling, Janssen Research & Development, LLC, Raritan, New Jersey, United States

Pei-Ling Chu,

• de Zeeuw, Dick, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Dick de Zeeuw,

• L Heerspink, Hiddo Jan, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Hiddo Jan L Heerspink,

• Kavalam, Mary, Janssen Research & Development, LLC, Raritan, New Jersey, United States

Mary Kavalam,

• Pollock, Carol A., Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia

Carol A. Pollock,

• Sun, Tao, Janssen Research & Development, LLC, Raritan, New Jersey, United States

Tao Sun,

• Zinman, Bernard, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

Bernard Zinman,

• Perkovic, Vlado, The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia

Vlado Perkovic,

• Bakris, George L., University of Chicago Medicine, Chicago, Illinois, United States

George L. Bakris,

Background

CANA reduces kidney failure and CV events in people with type 2 diabetes who have chronic kidney disease. Given the international scope of the CREDENCE study, we assessed the efficacy of CANA according to self-reported race and ethnicity.

Methods

4401 participants with eGFR 30-<90mL/min/1.73m² and urinary albumin:creatinine ratio >300-5000mg/g were randomized to CANA 100mg daily or matching placebo. Outcomes were analyzed in prespecified analyses by race and ethnicity, and results are reported without adjustment for multiplicity.

Results

The cohort enrolled were racially and ethnically diverse (n=2931 [67%] White, n=224 [5%] Black or African American, n=877 [20%] Asian, n=369 [8%] Other race, n=1423 [32%] Hispanic/Latino, n=2978 [68%] Non Hispanic/Latino [including not reported/unknown ethnicity]). CANA reduced the primary outcome of end-stage kidney disease (ESKD), sustained doubling serum creatinine (dSCr), or renal or CV death overall, with no evidence the effect differed in racial (P interaction=0.91) and ethnic subgroups (P interaction=0.31; Figure). Similarly, CANA reduced CV outcomes and the renal composite of ESKD, sustained dSCr or renal death, with no differences among the different racial and ethnic groups (all P interaction≥0.06).

Conclusion

CANA reduces the incidence of renal and CV events in people with type 2 diabetes and substantial albuminuria, with no evidence that effects differ in racial or ethnic groups, thereby supporting the breadth of use across a diverse group of patients.

Funding

• Commercial Support –